M. Tech Clinical engineering

IDEX Biometrics and M-Tech to scale Biometric Payment Cards in India

Retrieved on: 
Wednesday, November 30, 2022
VISA, Smart card, Mastercard, Hacking, IATF 16949, OSE, CMMI, IDEX Biometrics, World Bank Governance Surveys, IATF, RuPay, RFID, Corporation, Risk, Partnership, IDEX, Bachelor of Engineering, Government, Infineon Technologies, M. Tech Clinical engineering, Name, Aadhaar, Application, Visa, ISO, Payment card, Security printing

Oslo, Norway and Pune, India - 30 November 2022 - IDEX Biometrics ASA is bringing biometric payment cards to the Indian market, in partnership with technology provider M-Tech Innovations Ltd.

Key Points: 
  • Oslo, Norway and Pune, India - 30 November 2022 - IDEX Biometrics ASA is bringing biometric payment cards to the Indian market, in partnership with technology provider M-Tech Innovations Ltd.
  • The biometric solution is based on IDEX Biometrics TrustedBio sensor module, powered by SLC38 from Infineon Technologies.
  • Catharina Eklof, Chief Commercial Officer of IDEX Biometrics, says, The Indian market represents a very large opportunity for biometric payment cards.
  • The booming smart card market in India represents an excellent opportunity for the biometric card solution from IDEX Biometrics, says VM Gandhi, Chairman of M-Tech.

Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer

Retrieved on: 
Tuesday, September 28, 2021
Bachelor of Technology, GMP, Neoplasm, Financial compensation, MIT, Neurotensin receptor, Novartis, IIT, Employment, Indian Institutes of Technology, NTSR1, CML, FDA, FGFR3, McMaster University, Patient, Multimedia, Institute, Chemical engineering, DNA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Board, Metabolism, Good manufacturing practice, Marketing, NASH, Merck, Company, Growth, Tat, Isotope, Harvard Business School, McKinsey & Company, AstraZeneca, IND, View, Radiopharmaceutical, Research, Drug development, M. Tech Clinical engineering, Pembrolizumab, Pharmaceutical industry, Management

HAMILTON, ONandBOSTON, Sept. 28, 2021 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Mohit Rawat as President and Chief Business Officer.

Key Points: 
  • HAMILTON, ONandBOSTON, Sept. 28, 2021 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Mohit Rawat as President and Chief Business Officer.
  • Mr. Rawat brings to Fusion more than 15 years of experience in the biopharmaceutical industry, with expertise in corporate strategy, business development and commercial execution, including product development, launch planning and commercialization.
  • Before joining Novartis, Mr. Rawat was asset team lead, senior director, immunology and neuroscience at AbbVie Pharmaceuticals.
  • Earlier in his career, Mr. Rawat held several positions of increasing responsibility within Novartis Pharmaceuticals, across marketing and sales, drug development and portfolio planning.